Agonist News and Research

RSS

Simple blood test could identify the most effective obesity drug

Fasting blood tests measuring GLP-1 and GIP levels may predict obesity treatment response to semaglutide and tirzepatide, enhancing personalized therapy.

29 Jun 2026

Semaglutide approval drove a surge in GLP-1 poison center exposures

Following semaglutide's approval, poison center reports of GLP-1 RA exposures doubled, revealing critical trends in patient safety and healthcare utilization.

26 Jun 2026

New oral drug shows promise for chronic heart failure treatment

An early clinical study shows that a new oral drug is safe and well-tolerated in patients with chronic heart failure.

24 Jun 2026

England faces widening obesity inequalities across regions and communities

This study is the first to analyse obesity trends from 2019 to 2025, using NHS England electronic health records covering nearly 55 million adults.

24 Jun 2026

Weight-loss medications lessen the risk of violent criminal behavior

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for diabetes and obesity, but studies have found evidence that the medications may also influence behavior, such as supporting impulse control and reducing substance use and alcohol consumption by potentially interacting with the brain's reward and stress systems.

17 Jun 2026

GLP-1 medications may reduce violent behavior in adults

The use of GLP-1 medications commonly prescribed for weight loss or managing diabetes may have effects that extend beyond metabolic health, including on behaviors linked to violence, according to Rutgers researchers.

17 Jun 2026

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

Tirzepatide outperforms semaglutide for real-world weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become massively popular for weight loss, but results vary from person to person and drug to drug.

16 Jun 2026

Physical activity declines after starting GLP-1 obesity treatments

Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which is essential to protect muscle, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

New guideline recommends tailored care for precocious puberty

Some subgroups of children with precocious puberty-such as older girls with slowly progressing puberty-may not need the same level of testing or treatment, according to a new Endocrine Society Clinical Practice Guideline released today.

14 Jun 2026

Parkinson's drug may ease anhedonia in treatment-resistant depression

For many people who suffer from depression, the condition is not just about feeling down, but also about a loss of motivation and difficulty finding pleasure in activities they used to enjoy.

12 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

GLP-1 medicines may cut clot-related risks in chronically inflamed patients

In a target trial emulation using OneFlorida+ electronic health record data, GLP-1 receptor agonist use in adults with obesity and autoimmune disease was linked to lower hazards of pulmonary embolism, venous thromboembolism, stroke/TIA, emergency department visits, and all-cause mortality.

10 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026

Oral GLP-1 RA reduces blood glucose and bodyweight among people with type 2 diabetes

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight.

8 Jun 2026

Weight loss drugs linked to lower risk of alcohol, opioid, nicotine and cocaine use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

8 Jun 2026

GLP-1 therapies linked to fewer complications in adults with both obesity and autoimmune disease

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

7 Jun 2026

Histamine boost helps the brain remember, decide, and learn from loss

Pitolisant, a histamine H3 receptor inverse agonist, improved recognition memory, working memory performance, and reinforcement learning in healthy adults. The findings suggest that histamine helps shape how the brain stabilizes new memories, accumulates evidence for decisions, and avoids overreacting to negative outcomes.

3 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026